Nitric Oxide Signaling in Heart Failure With Preserved Ejection Fraction
| Autor: | Lucas Cruz, John J. Ryan |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2017 |
| Předmět: |
medicine.medical_specialty
lcsh:Diseases of the circulatory (Cardiovascular) system Sildenafil sildenafil 030204 cardiovascular system & hematology Nitric oxide nitrites 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine pulmonary arterial hypertension Internal medicine medicine 030212 general & internal medicine nitrates business.industry Phosphodiesterase Journal Watch medicine.anatomical_structure chemistry Ventricle Vardenafil lcsh:RC666-701 Cardiology Cardiology and Cardiovascular Medicine Heart failure with preserved ejection fraction business phosphodiesterase medicine.drug Nitric oxide signaling |
| Zdroj: | JACC: Basic to Translational Science, Vol 2, Iss 3, Pp 341-343 (2017) JACC: Basic to Translational Science |
| Popis: | Summary There has been considerable focus on the potential role of nitric oxide (NO) and phosphodiesterase (PDE)-5 inhibition in treating heart failure with preserved ejection fraction (HFpEF). However, the results from studies have been conflicting. In a preclinical study, pre-treatment of diabetic rats with a PDE-5 inhibitor, vardenafil, resulted in a significant decrease in left ventricle stiffness. However, the results from clinical trials have been neutral. In this perspective piece, the authors discuss whether or not it is time to move on from targeting NO and PDE5 for the treatment of HFpEF. Corresponding Author |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|